Quantcast

Latest IMS Health Stories

2014-05-09 12:26:41

BRIDGEWATER, N.J., May 9, 2014 /PRNewswire/ -- Ajanta Pharma USA Inc., a wholly owned subsidiary of Ajanta Pharma Ltd, announced today the launch of Risperidone Tablets (0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg), the generic version of Risperdal®[1]. Risperidone Tablets are used to treat schizophrenia and bipolar disorder. According to IMS Health, sales of branded and generic products totalled approximately $147 million for the 12 months ending March 2014[2]. Ajanta Pharma's launch of...

2014-04-23 12:29:37

New Entity YL Biologics to focus on clinical development and commercialization of Biosimilars for Japan MUMBAI and BALTIMORE, April 23, 2014 /PRNewswire/ -- Pharma Major, Lupin Limited (Lupin) announced today that it has entered into a strategic joint venture agreement with Toyama based Japanese pharmaceuticals company, Yoshindo Inc. (Yoshindo) to create a new entity, YL Biologics (YLB). YLB will be jointly managed by both partners and will be responsible for conducting...

2014-04-22 12:28:53

DALLAS, April 22, 2014 /PRNewswire/ -- According to new research report "Population Health Management Market by Component (Software & Services), Delivery Mode (On-premise, Web, & Cloud), End-User (Provider, Payer, Employer Groups & Government Bodies) - Trends & Global Forecasts to 2018" published by MarketsandMarkets, This market was valued at $12.8 Billion in 2013 and is poised to grow at a CAGR of 26% from 2013 to 2018, to reach $40.6 Billion by 2018....

2014-04-21 12:26:38

MUMBAI, India and BALTIMORE, April 21, 2014 /PRNewswire/ -- Pharma major Lupin today announced the appointment of Theresa Stevens as Chief Corporate Development Officer for its global operations. Theresa will assume full responsibility for global merger and acquisitions and specialty business strategy. Prior to joining Lupin, Theresa was with Aptalis pharma as the Chief Corporate Development Officer responsible for Mergers & Acquisitions (M&A), Strategy and Global...

2014-04-16 23:08:20

Brody will lead Kantar Health’s partnerships and acquisitions activities. New York, NY (PRWEB) April 16, 2014 Kantar Health, a leading global healthcare consulting firm, has named Jeremy Brody as Executive Vice President, Corporate Development. In his new role, Brody will lead Kantar Health’s partnerships and acquisitions activities as well as continue to oversee the firm’s strategy for incorporating digital and mobile into its research programs. Brody is based near Tel Aviv,...

2014-04-16 16:30:46

PITTSBURGH, April 16, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched XULANE(TM) (Norelgestromin / Ethinyl Estradiol Transdermal System 150/35 mcg per day), the generic version of Janssen Pharmaceuticals Inc.'s ORTHO EVRA®* (Norelgestromin / Ethinyl Estradiol Transdermal System 150/35 mcg per day). This product is indicated for the prevention of pregnancy in women who elect to use a transdermal patch...

2014-04-15 16:26:50

DUBLIN, April 15, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/9b46rc/healthcare ) has announced the addition of the "Healthcare Analytics/Medical Analytics Market by Application, Type, End-user, Delivery Mode - Trends & Global Forecasts to 2020" [http://www.researchandmarkets.com/research/9b46rc/healthcare ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Healthcare analytics...

2014-04-15 12:30:09

PITTSBURGH, April 15, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that it and its partner Famy Care Ltd. have entered into a settlement and license agreement with Warner Chilcott Company, LLC, settling the parties' litigation in connection with Mylan's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Norethindrone and Ethinyl Estradiol Chewable Tablets 0.8 mg/0.025 mg and Ferrous Fumarate Chewable Tablets. This...

2014-04-11 08:24:31

PITTSBURGH, April 11, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that a federal district court has granted its request to enforce a settlement agreement between Endo Pharmaceuticals and Mylan settling patent litigation in connection with Mylan's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Frovatriptan Succinate Tablets, 2.5 mg. This product is the generic version of FROVA(®), which is used to treat acute...

2014-03-27 12:30:57

Specialty Ophthalmic Company in Mexico; Enters the Latin American Market MUMBAI, India and BALTIMORE, March 27, 2014 /PRNewswire/ -- Pharma Major Lupin Limited announced today the acquisition of 100% equity stake in Laboratorios Grin, S.A. De C.V. (Grin), Mexico, subject to certain closing conditions. The acquisition marks Lupin's foray into the high growth Mexican and the larger Latin American pharmaceuticals market. Mexico is one of the fastest growing pharmaceutical markets in the...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related